Clinical Trials Logo

Filter by:
NCT ID: NCT01376973 Completed - Clinical trials for Stress, Psychological

Efficiency of Two Occlusal Splints on TMD Treatment of Police Officers

Start date: March 2008
Phase: N/A
Study type: Observational

Stress is an important cause factor of temporomandibular disorder (TMD) and Police Officers are exposed to stress. Aim of the study was to evaluate clinical and electromyographically the effect of two different occlusal splints on police officers with TMD

NCT ID: NCT01376804 Completed - Clinical trials for Kidney Transplantation, Cytomegalovirus Infections

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

Start date: July 2011
Phase: Phase 4
Study type: Interventional

This open-label, single arm study will evaluate the tolerability and efficacy of Valcyte (valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant recipients. After transplantation, patients (aged 4 months to 16 years) will receive Valcyte orally daily for up to 200 days post-transplant and will be followed for 52 weeks post-transplantation.

NCT ID: NCT01376167 Completed - Malaria, Vivax Clinical Trials

Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

Start date: April 24, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this two part study is to test the safety and efficacy of Tafenoquine (with Cholorquine) as a radical cure for Plasmodium vivax (P.vivax) malaria relative to the control Chloroquine.Part 1 aims to select an efficacious and well tolerated dose that can be co-administered with Chloroquine. Part 2 will investigate the safety and efficacy of the selected dose (300 mg tafenoquine) in the treatment and radical cure of Plasmodium Vivax Malaria.

NCT ID: NCT01375127 Completed - Clinical trials for Kidney Transplantation

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Start date: August 2011
Phase: N/A
Study type: Observational

This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.

NCT ID: NCT01374906 Completed - Cushing's Disease Clinical Trials

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Start date: November 4, 2011
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.

NCT ID: NCT01374516 Completed - Dengue Clinical Trials

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Start date: June 8, 2011
Phase: Phase 3
Study type: Interventional

The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America. Primary Objective: To assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the severity, due to any of the four serotypes in children and adolescents aged 9 to 16 years at the time of inclusion. Secondary Objectives: - To describe the efficacy of CYD dengue vaccine in preventing symptomatic VCD cases after the third dose to the end of the Active Phase, after at least 1 dose, and after 2 doses. - To describe the occurrence of hospitalized VCD cases and the occurrence of severe (clinically severe or as per World Health Organization (WHO) criteria) VCD cases, throughout the Surveillance Expansion Period (SEP) and throughout the trial (from Day 0 until the end of the study). - To describe the antibody response to each dengue serotype after Dose 2, after Dose 3, and 1 and 5 years after Dose 3. - To describe the occurrence of serious adverse events (SAEs), including SAEs of special interest in all participants throughout the trial period.

NCT ID: NCT01374451 Completed - Islet Cell Tumor Clinical Trials

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

COOPERATE-1
Start date: June 2011
Phase: Phase 2
Study type: Interventional

This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET

NCT ID: NCT01374022 Completed - Clinical trials for Respiratory Distress Syndrome, Adult

ART - Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial

ART
Start date: June 2011
Phase: N/A
Study type: Interventional

Acute respiratory distress syndrome (ARDS) is a common scenario in intensive care unit. Discussions about it is exponentially growing up due its high mortality rates all over the world and low quality of life among survivors. Mechanical ventilation is recognized to play an important role in treatment of patients with ARDS. However, mechanical ventilation itself has the potential to produce or worsen alveolar injury if inadequate strategies are chosen. Several studies compared different mechanical ventilation strategies in ARDS but the results remain uncertain regarding their influence on survival in patients with ARDS. Thus, this is a multicentric randomized controlled trial, with allocation concealment and intention to treat analysis to investigate if maximum alveolar recruitment maneuver in association to Positive end-expiratory pressure (PEEP) titrated by static compliance of respiratory system (ART strategy) is able to increase 28 days survival in patients with moderate to severe ARDS compared to conventional strategy proposed by the ARDS Clinical Network (ARDSNet strategy). Patients considered to this trial are those in mechanical ventilation with diagnosis of moderate to severe ARDS less than 72hours. Patients included will be randomized to receive ART strategy or ARDSNet strategy and will be followed until hospital discharge, 28 days and 6 months.

NCT ID: NCT01373151 Completed - Clinical trials for Rheumatoid Arthritis

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.

NCT ID: NCT01372865 Completed - Clinical trials for Mild to Moderate Persistent Allergic Rhinitis

A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)

Start date: June 2012
Phase: Phase 3
Study type: Interventional

The primary objective will be to compare the impact of the study formulations on alergic rhinitis carriers.